| Literature DB >> 33060738 |
M Korabecna1, A Zinkova2, I Brynychova2,3, B Chylikova2, P Prikryl4, L Sedova2, P Neuzil5,6, O Seda2.
Abstract
The cell-free DNA (cfDNA) is always present in plasma, and it is biomarker of growing interest in prenatal diagnostics as well as in oncology and transplantology for therapy efficiency monitoring. But does this cfDNA have a physiological role? Here we show that cfDNA presence and clearance in plasma of healthy individuals plays an indispensable role in immune system regulation. We exposed THP1 cells to healthy individuals' plasma with (NP) and without (TP) cfDNA. In cells treated with NP, we found elevated expression of genes whose products maintain immune system homeostasis. Exposure of cells to TP triggered an innate immune response (IIR), documented particularly by elevated expression of pro-inflammatory interleukin 8. The results of mass spectrometry showed a higher abundance of proteins associated with IIR activation due to the regulation of complement cascade in cells cultivated with TP. These expression profiles provide evidence that the presence of cfDNA and its clearance in plasma of healthy individuals regulate fundamental mechanisms of the inflammation process and tissue homeostasis. The detailed understanding how neutrophil extracellular traps and their naturally occurring degradation products affect the performance of immune system is of crucial interest for future medical applications.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33060738 PMCID: PMC7566599 DOI: 10.1038/s41598-020-74288-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Differentially expressed genes in cells treated with native plasma (NP) and with DNAase treated plasma (TP). (a) Comparison of gene expression in THP1 cells cultivated with NP versus TP (GeneChip Human Gene 2.1 ST Array Strip technology, Supplementary Data Table 1). Analysis performed and graph derived using Transcriptome Analysis Console 4.0 (https://www.thermofisher.com/cz/en/home/life-science/microarray-analysis/microarray-analysis-instruments-software-services/microarray-analysis-software/affymetrix-transcriptome-analysis-console-software.html). (b) Genes overexpressed in THP1 cells treated with NP—results of validation qPCR experiments normalized to the PGK1 gene. AU = arbitrary unit, graphs generated using GraphPad Prism 5.00.288 software, https://www.graphpad.com. (c) Genes overexpressed in THP1 cells treated with TP—results of validation. (d) Results of validation qPCR experiments given as fold changes.
Results of analysis performed using the Reactome database. (a) Over-represented pathways for genes upregulated in THP1 cells treated with NP and (b) cells treated with TP; (c) Over-represented pathways for proteins upregulated in THP1 cells treated with TP (FDR false discovery rate with Benjamini–Hochberg adjustment).
| Process | Pathway name | FDR | Genes |
|---|---|---|---|
| Unfolded protein response (UPR) maintains immune system homeostasis | ATF4 activates genes in response to endoplasmic reticulum stress | 1.28 × 10−6 | |
| PERK regulates gene expression | 1.52 × 10−6 | ||
| Unfolded Protein Response | 1.38 × 10−6 | ||
| ATF6 (ATF6-alpha) activates chaperone genes | 8.90 10−4 | ||
| Constitutive tonic NOTCH signaling | RUNX3 regulates NOTCH signaling | 8.16 × 10−6 | |
| NOTCH1 Intracellular Domain Regulates Transcription | 3.00 × 10−3 | ||
| Signaling by NOTCH1 | 5.00 × 10−3 | ||
| Regulation of RNA polymerase II transcription | Generic transcription pathway | 9.49 × 10−4 | |
| RNA polymerase II Transcription | 1.00 × 10−3 | ||
| Innate immune response activated by UPR | ATF4 activates genes in response to endoplasmic reticulum stress | 8.32 × 10−4 | |
| PERK regulates gene expression | 8.32 × 10−4 | ||
| Interleukin signaling | Interleukin-10 signaling | 2.00 × 10−3 | |
| Interleukin-1 and interleukin-13 signaling | 6.00 × 10−3 | ||
| Cellular senescence | Senescence associated secretory phenotype | 2.00 × 10−3 | |
| Complement activation | Complement cascade | 1.34 × 10−10 | SERPING1, CFHR5, C7, C9, CFD, C1QB, C1QA, C1QC, C1S, CFH, C1R, C4B, C3, C5, C6 |
| Regulation of complement cascade | 1.34 × 10−10 | SERPING1, CFHR5, C7, C9, C1QB, C1QA, C1QC, C1S, CFH, C1R, C4B, C3, C5, C6 | |
| Terminal pathways of complement | 5.39 × 10−4 | C7, C9, C5, C6 | |
| Initial triggering of complement | 9.00 × 10−3 | C1S, C1R, CFD, C1QB,C4B, C3, C1QA, C1QC | |
Figure 2(a) Differentially expressed canonical pathways detected by IPA in THP1 cells treated with TP versus NP with a threshold value set to − 1.53, corresponding to the statistical significance level (α) value of 0.03. (b) Differentially expressed disease-specific pathways detected by IPA in THP1 with TP versus NP with a threshold value set to − 1.3, corresponding to the α value of 0.05. The analyses were generated through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) Inset: Differentially upregulated pathways in THP1 cells cultivated with native plasma and plasma treated with DNAse as detected using the Reactome database. LXR stands for liver X receptor, RXR for retinoid X receptor, and FXR for farnesoid X receptor.
Figure 3Target downstream biological pathways predicted by IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). The intensity of the red color mirrors the level of upregulation; the green color is used for downregulation.